Last updated: 11/03/2018 10:59:38
Food and relative bioavailability studyFood/rel BA
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A open-label, randomized, single-dose, 3-way crossover study to investigate the pharmacokinetics, safety and tolerability of 2 different formulations of orvepitant and the effect of food in healthy volunteers.
Trial description: This study is an open-label, randomised, single dose study to determine thepharmacokinetics, safety and tolerability of 2 different formulations of orvepitant 60 mgand the effect of food in 15 Healthy Volunteers.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Pharmacokinetic:parameters of orvepitant: tlag, tmax, Cmax, AUC(0-t), AUC (0-∞), t1/2.
Timeframe: 72 hours post dose.
Safety and tolerability endpoints will be evaluated by adverse event monitoring,laboratory values, cardiovascular monitoring
Timeframe: 5 weeks.
Secondary outcomes:
Not applicable
Interventions:
Enrollment:
14
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Depressive Disorder
Product
orvepitant
Collaborators
Not applicable
Study date(s)
August 2008 to October 2008
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Healthy male or female between 18 and 65 years of age inclusive.
- A female subject is eligible to participate if she is of either non-childbearing potential or child-bearing potential and agrees to use one of the contraception methods
- As a result of any of the medical interview, physical examination or screening
- investigations the Physician Responsible considers the subject unfit for the study.
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy male or female between 18 and 65 years of age inclusive.
- A female subject is eligible to participate if she is of either non-childbearing potential or child-bearing potential and agrees to use one of the contraception methods
- No co-morbid Psychiatric Disorders as defined using the Mini International Neuropsychiatric Interview (M.I.N.I) scale.
- A 12-lead ECG at screening showed no abnormalities that in the opinion of the Principal Investigator will compromise safety in this study. -- Body weight ≥ 50 kg and BMI within the range 19.0 – 29.9 kg/m2 (inclusive).
- Capable of giving written informed consent
Exclusion criteria:
- As a result of any of the medical interview, physical examination or screening investigations the Physician Responsible considers the subject unfit for the study.
- The subject has a history of a drug or other allergy which in the opinion of the Physician Responsible contraindicates the participation in the study.
- Subjects with an unstable medical disorder or a disorder that would likely interfere with the action, absorption, distribution, metabolism or excretion of orvepitant, may pose a safety concern, or interfere with accurate assessment of safety.
- The subject has a current or recent (within six months) documented gastrointestinal disease; a history of malabsorption, oesophageal reflux, or irritable bowel syndrome; frequent (more than once a week) occurrence of heartburn, or any surgical intervention (e.g. cholecystectomy) which would be expected to influence the absorption of drugs.
- History of psychiatric illness
- Any history of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure).
- Subject is consuming alcool or tobacco
- Subject is positive to Hepatitis B, C or HIV
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2008-23-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 110355 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website